1996 Fiscal Year Final Research Report Summary
Experimental and clinical studies on intraperitoneal osmotic chemotherapy for disseminated peritoneal carcinomatosis
| Project/Area Number |
06671275
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Faculty of Medicine, Tottori University |
|---|
Principal Investigator |
KAIBARA Nobuaki Tottori Univ., Dept.of Surg.I Professor, 医学部, 教授 (70037406)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUJITANI Syunichi Tottori Univ., Dept.of Surg.I Assistant, 医学部, 助手 (30188544)
MAETA Michio Tottori Univ., Dept.of Surg.I Associate Professor, 医学部, 助教授 (70032208)
|
|---|
| Project Period (FY) |
1994 – 1996
|
| Keywords | osmotic chemotherpy / peritoneal carcinomatosis / cisplatin |
|---|
| Research Abstract |
1) Experimental study
The intraperitoneal (i.p.) administration of cisplatin is one of the most effective therapies for cancers that are confined to the abdominal cavity. However, the effect of osmolarity on the therapeutic efficacy of i.p. administration of cisplatin has not been well established. In this series, hypotonic (154mOsM), isotonic (308mOsM) and hypertonic (616mOsM) solutions of cisplatin were prepared for an evaluation of their therapeutic efficacy in an experimental system. After i.p. administration, uptake of cisplatin in vivo by tumor cells in hypotonic solution was significantly greater than in isotonic or hypertonic solution. The 50 % lethal dose (LD50) value of cisplatin hypotonic solution (12.1 mg/kg) was lower than that in isotonic solution (16.9 mg/kg) and than that in hypertonic solution (28.6 mg/kg). However, when a dose equal to one-half of the LD50 was administered in each solution to mice with i.p. tumors, survival of mice given the cisplatin in hypotonic solution was significantly prolonged as compared with the survival of the other mice. These results demonstrate that the therapeutic efficacy of i.p. cisplatin in mice is augmented when the drug is administered in hypotonic solution.
2) Chliinical study
Clinical phase II study revealed that appropriate dose of cisplatin and osmolarity in the clinical setting were 70 mg/m^2 and 154 mOsM,respectively. We are now studying the prophylactic effect of hypotonic intraperitoneal cisplatin chemotherapy on postoperative peritoneal metastasis in patients with gastric cancer with serosal invasion, as a prospective randomized study.
|
-
-
-
-
-
-
-
-
[Publications] S.Tsujitani, A.Oka, A.Kondo, K.Katano, H.Saito, M.Ikeguchi, M.Maeta, N.Kaibara.: Hypotonic intraperitoneal cisplatin for cancer spreading to the peritoneum. Recent Advances in Gastroenterological Carcinogenesis (E.Tahara, K.Sugimachi, T.Oohara, eds). Monduzzi Editore, 1139-1143 (1996)
Description
「研究成果報告書概要(欧文)」より
